Showing 61 to 72 of 215 results
Trump Administration Explores Psychedelics for PTSD Treatment
The Trump administration is exploring the use of psychedelics, such as MDMA and psilocybin, to treat PTSD and other mental health conditions, based on promising clinical trial results and driven by a need for effective alternative treatments; the Department of Veterans Affairs is currently conductin...
Trump Administration Explores Psychedelics for PTSD Treatment
The Trump administration is exploring the use of psychedelics, such as MDMA and psilocybin, to treat PTSD and other mental health conditions, based on promising clinical trial results and driven by a need for effective alternative treatments; the Department of Veterans Affairs is currently conductin...
Progress
48% Bias Score
FDA Launches Comprehensive Review of Infant Formula Regulations
The FDA is leading a comprehensive review of infant formula regulations, prompted by concerns about ingredient safety and outdated standards, aiming to modernize US formulas and make them a global gold standard.
FDA Launches Comprehensive Review of Infant Formula Regulations
The FDA is leading a comprehensive review of infant formula regulations, prompted by concerns about ingredient safety and outdated standards, aiming to modernize US formulas and make them a global gold standard.
Progress
44% Bias Score
US Alters COVID-19 Vaccine Recommendations, Raising Concerns About Access and Public Health
The Trump administration ended routine COVID-19 vaccination recommendations for healthy pregnant women, children, and adults under 65, potentially limiting insurance coverage and causing confusion among healthcare providers and the public due to differing opinions on vaccine efficacy and safety.
US Alters COVID-19 Vaccine Recommendations, Raising Concerns About Access and Public Health
The Trump administration ended routine COVID-19 vaccination recommendations for healthy pregnant women, children, and adults under 65, potentially limiting insurance coverage and causing confusion among healthcare providers and the public due to differing opinions on vaccine efficacy and safety.
Progress
48% Bias Score
FDA Clears New Blood Test for Alzheimer's Diagnosis
The FDA approved the Lumipulse G Plasma Ratio blood test for Alzheimer's, offering a less invasive and potentially cheaper diagnostic for patients over 55 with cognitive decline; the test achieved 92% accuracy in clinical trials detecting amyloid and tau proteins.
FDA Clears New Blood Test for Alzheimer's Diagnosis
The FDA approved the Lumipulse G Plasma Ratio blood test for Alzheimer's, offering a less invasive and potentially cheaper diagnostic for patients over 55 with cognitive decline; the test achieved 92% accuracy in clinical trials detecting amyloid and tau proteins.
Progress
44% Bias Score
FDA Issues Class I Recall of Williams Farms Tomatoes Due to Salmonella Risk
Williams Farms Repack LLC recalled several sizes of vine-ripe tomatoes sold in Georgia, North Carolina, and South Carolina from April 23-28 due to potential salmonella contamination; the FDA issued a Class I recall, its most serious classification, despite no reported illnesses.
FDA Issues Class I Recall of Williams Farms Tomatoes Due to Salmonella Risk
Williams Farms Repack LLC recalled several sizes of vine-ripe tomatoes sold in Georgia, North Carolina, and South Carolina from April 23-28 due to potential salmonella contamination; the FDA issued a Class I recall, its most serious classification, despite no reported illnesses.
Progress
52% Bias Score
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
FDA Recommends Covid-19 Vaccine Update, Mandating Trials for Healthy Individuals
The FDA recommends updating Covid-19 vaccines to target the LP.8.1 strain, the dominant U.S. variant, but new rules mandate placebo-controlled trials for healthy individuals, potentially delaying widespread access while over 100 million remain eligible.
Progress
40% Bias Score
Salmonella Outbreak Linked to Recalled Eggs Sickens 79
Over 70 people across nine US states have been sickened in a salmonella outbreak traced to 1.7 million dozen eggs recalled by August Egg Company; 21 were hospitalized, and the eggs were sold at major retailers including Walmart and Safeway.
Salmonella Outbreak Linked to Recalled Eggs Sickens 79
Over 70 people across nine US states have been sickened in a salmonella outbreak traced to 1.7 million dozen eggs recalled by August Egg Company; 21 were hospitalized, and the eggs were sold at major retailers including Walmart and Safeway.
Progress
16% Bias Score
FDA Launches Comprehensive Infant Formula Review
The US Food and Drug Administration is leading a comprehensive review of infant formula regulations, prompted by concerns over outdated guidelines and potential health risks associated with current ingredients and manufacturing practices. The review will consider the source of fats, carbohydrates, s...
FDA Launches Comprehensive Infant Formula Review
The US Food and Drug Administration is leading a comprehensive review of infant formula regulations, prompted by concerns over outdated guidelines and potential health risks associated with current ingredients and manufacturing practices. The review will consider the source of fats, carbohydrates, s...
Progress
52% Bias Score
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Groundbreaking Cancer Therapy Shows Remarkable Success in Late-Stage Prostate Cancer
A California study of 15 men with late-stage prostate cancer showed that 53% achieved complete remission using SYNC-T, a novel therapy involving tumor cryotherapy followed by localized immunotherapy; this exceeded expected survival rates, offering new hope for patients with limited treatment options...
Progress
48% Bias Score
FDA Requires New COVID-19 Vaccine Trials, CDC Offers Broader Access
The FDA requires new clinical trials for COVID-19 vaccines' effectiveness in healthy people under 65 before broader approval, while the CDC's immunization schedule includes them as an option, prompting questions about access and cost; insurance companies might demand medical documentation for covera...
FDA Requires New COVID-19 Vaccine Trials, CDC Offers Broader Access
The FDA requires new clinical trials for COVID-19 vaccines' effectiveness in healthy people under 65 before broader approval, while the CDC's immunization schedule includes them as an option, prompting questions about access and cost; insurance companies might demand medical documentation for covera...
Progress
52% Bias Score
FDA Clears Lumipulse Blood Test for Early Alzheimer's Detection
The FDA cleared Lumipulse, a blood test detecting Alzheimer's amyloid plaques in symptomatic adults over 55, improving early diagnosis and access to new treatments, potentially reducing reliance on expensive and invasive procedures.
FDA Clears Lumipulse Blood Test for Early Alzheimer's Detection
The FDA cleared Lumipulse, a blood test detecting Alzheimer's amyloid plaques in symptomatic adults over 55, improving early diagnosis and access to new treatments, potentially reducing reliance on expensive and invasive procedures.
Progress
44% Bias Score
FDA to Deploy Generative AI Agency-Wide by June 2025
The FDA announced plans to deploy generative AI enterprise-wide by June 2025, following a successful pilot program that demonstrated significant time savings in document review and scientific analysis, aiming to accelerate the review process for new therapies without compromising safety, privacy, or...
FDA to Deploy Generative AI Agency-Wide by June 2025
The FDA announced plans to deploy generative AI enterprise-wide by June 2025, following a successful pilot program that demonstrated significant time savings in document review and scientific analysis, aiming to accelerate the review process for new therapies without compromising safety, privacy, or...
Progress
44% Bias Score
Showing 61 to 72 of 215 results